IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Novavax, Inc. v GlaxoSmithKline Biologicals SA [2018] APO 84
Patent Application: 2012211278
Title:RSV immunization regimen
Patent Applicant: GlaxoSmithKline Biologicals SA
Opponent: Novavax, Inc
Delegate: D. S. Triffett
Decision Date: 23 November 2018
Hearing Date: 31 August 2018, in Canberra
Catchwords: PATENTS – section 59 opposition to grant of a patent – manner of manufacture – lack of manner of manufacture not established – novelty – lack of novelty not established – inventive step – evidence does not establish that a person skilled in the art would ascertain patent documents - lack of inventive step not established – full description – lack of full description not established – best method of performance – lack of best method of performance not established
Representation: Counsel for the applicant: Mr Chris Burgess
Patent attorney for the applicant: Mr Steve Gledhill and Dr Lee Miles of FB Rice
Counsel for the opponent: Mr Ian Horak
Patent attorney for the opponent: Dr Tom Gumley and Dr Catherine Windbanks of FPA Patent Attorneys Pty Ltd.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2012211278
Title: RSV immunization regimen
Patent Applicant: GlaxoSmithKline Biologicals SA.
Date of Decision: 23 November 2018
DECISION
The opposition fails on all grounds. Subject to appeal, I direct that the application proceed to grant.
I award costs according to Schedule 8 against Novovax, Inc.
REASONS FOR DECISION
Background
Patent application 2012211278 in the name of GlaxoSmithKline Biologicals SA (the applicant) was advertised as accepted on 10 November 2016. Novavax, Inc (the opponent) opposed the grant of a patent under s 59 of the Patents Act 1990 (Cth)(the Patents Act).
The opposition
The statement of grounds and particulars identified seven grounds of opposition: manner of manufacture, novelty, inventive step, utility, full description, clarity and fair basis. At the hearing, only four grounds were pressed: manner of manufacture, novelty, inventive step and full description.
The parties relied upon evidence by several declarants. Evidence in support consists of declarations by John Lowenthal (Lowenthal-1 and Lowenthal-2), Nigel Crawford (Crawford-1 and Crawford-2), and Catherine Windbanks (Windbanks). Evidence in answer consists of a declaration by Paul Young (Young). Evidence in reply consists of declarations by John Lowenthal (Lowenthal-3) and Nigel Crawford (Crawford-3).
The request for examination in relation to the patent application was filed on 12 April 2013. As a consequence, the substantive amendments of the Patents Act brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the opposed application. This includes the amendment to s 60(3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition has been made out. Instead, the onus of proof in this opposition proceeding lies with the opponent, who must establish that it is clear that a valid patent cannot be granted.[1]
Keep reading for free
Create a free CaseChat account to read Novavax, Inc. v GlaxoSmithKline Biologicals SA and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] APO 84
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.